|
|
Thomson Reuters Business Description:
| Aethlon Medical, Inc. is a developmental-stage medical device company focused on the applications of the Hemopurifier platform technology, which is designed to reduce the presence of infectious viruses from human blood. Hemopurifier is a candidate therapeutic device to assist in the treatment of a range of viral pathogens. Viral treatment targets include bio terror agents, pandemic threats, human immunodeficiency virus/ acquired immunodeficiency syndrome (HIV/AIDS) and hepatitis-C virus (HCV). On June 10, 2009, the Company disclosed the primary treatment focus of Hemopurifier would be HCV. The wholly owned subsidiaries of the Company are Aethlon, Inc., Cell Activation, Inc., Syngen Research, Inc. and Hemex, Inc. In October 2009, the Company established a wholly owned subsidiary, Exosome Sciences, Inc. |
|
Research Alerts:
|
Receive alerts on the latest reports on Aethlon Medical, Inc.
Subscribe to Research Alerts via RSS and never miss the latest research on your favorite companies. Just click the images above to add the feed directly to your favorite newsreader.
|
|
